Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer

This is a Phase 1 trial testing a new immunotherapy (FluBHPVE6E7) for people with advanced throat cancer (oropharyngeal cancer) caused by the HPV16 virus. The therapy aims to activate the immune system to fight the cancer by targeting viral proteins. **You may be eligible if...** - You are between 18 and 65 years old - You have a newly diagnosed, biopsy-confirmed HPV16-positive oropharyngeal (throat) squamous cell cancer at an advanced local stage (T2N2-3, T3N0-3, or T4N0-3, no distant spread) - Your tumor is accessible for biopsy and direct injection - Your general health is good (Karnofsky 70–100, ECOG 0 or 1) **You may NOT be eligible if...** - Your cancer has spread to distant organs - You have a second cancer not related to HPV16 - You had another cancer in the past 2 years (unless in full remission) - You are pregnant or breastfeeding - You have active viral infections (HIV, Hepatitis B/C, influenza, CMV/EBV) - You are taking immunosuppressive medications (steroids, methotrexate, TNF inhibitors, etc.) - You have an autoimmune condition such as lupus, multiple sclerosis, or Crohn's disease Talk to your doctor to see if this trial is right for you.